Clinical Trial

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
Protocol Amendment History 2 changes
notable Trial sites expanded: 93 -> 105 locations 2026-07-28
notable Trial sites expanded: 90 -> 93 locations 2026-06-24
Trial Details
NCT Number NCT07286006
Lead Sponsor Immunovant Sciences GmbH
Conditions Graves' Disease
Enrollment 372 participants
Start Date 2026-01-26
Primary Completion 2030-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-27